AMVUTTRA
AMVUTTRA (vutrisiran) is an FDA-approved RNA interference (RNAi) therapeutic indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adults. It works by reducing the production of the TTR protein in the liver, helping to slow disease progression and improve nerve function. Each preservative-free single-dose vial is formulated for subcutaneous injection and must be administered by a qualified healthcare provider.
InfusionMed USA, located in Carrollton, Texas, supplies AMVUTTRA and other specialty infusion and injectable therapies to hospitals, clinics, and mobile infusion providers across Dallas, Frisco, McKinney, The Colony, Lewisville, Plano, and neighboring North Texas regions. We maintain FDA-compliant cold-chain handling, secure storage, and timely delivery to ensure product integrity.
Available only for licensed healthcare facilities and infusion professionals.
Download Form